<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003690</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066793</org_study_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>950101</secondary_id>
    <secondary_id>276-97</secondary_id>
    <nct_id>NCT00003690</nct_id>
  </id_info>
  <brief_title>Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study of Flavopiridol in Combination With Cisplatin in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or&#xD;
      carboplatin in treating patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of flavopiridol and cisplatin in patients&#xD;
           with advanced solid tumors. (Part 1)&#xD;
&#xD;
        -  Determine the MTD of carboplatin when combined with flavopiridol in another group of&#xD;
           patients with advanced solid tumors. (Part 2)&#xD;
&#xD;
        -  Determine the toxic effects of these regimens in this patient population.&#xD;
&#xD;
        -  Determine the objective clinical response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of these regimens in this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of flavopiridol and cisplatin (part 1), followed by&#xD;
      a dose-escalation study of carboplatin (part 2).&#xD;
&#xD;
        -  Part 1: Patients receive flavopiridol IV over 24 hours. Two weeks later, patients&#xD;
           receive cisplatin IV over 2 hours immediately followed by flavopiridol IV over 24 hours.&#xD;
           Treatment with cisplatin/flavopiridol continues every 3 weeks in the absence of&#xD;
           unacceptable toxicity or disease progression.&#xD;
&#xD;
      Sequential dose escalation of flavopiridol is followed by sequential dose escalation of&#xD;
      cisplatin. Cohorts of 3-6 patients receive escalating doses of flavopiridol and then&#xD;
      cisplatin until the maximum tolerated dose (MTD) of the combination is determined. The MTD is&#xD;
      defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting&#xD;
      toxicity.&#xD;
&#xD;
        -  Part 2: Additional patients are accrued for part 2. Those patients receive carboplatin&#xD;
           IV over 30 minutes immediately followed by flavopiridol IV over 24 hours. Treatment&#xD;
           continues every 3 weeks in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of carboplatin until the MTD is determined.&#xD;
      The MTD is defined as in part 1.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 36-48 patients will be accrued for this study within 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Prostate Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unresectable advanced solid tumor for which no standard&#xD;
             therapy exists that is potentially curative or definitely capable of extending life&#xD;
             expectancy&#xD;
&#xD;
               -  Biopsy confirmation of recurrent tumors required, unless sole site of disease is&#xD;
                  inaccessible bony and/or pulmonary metastases&#xD;
&#xD;
          -  Eligible solid tumors include, but not are limited to, prostate cancer, breast cancer,&#xD;
             or melanoma&#xD;
&#xD;
          -  No lymphoma&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
               -  Patients with primary brain tumors are eligible if they are not receiving&#xD;
                  antiepileptic medication(s) but are receiving stable doses of corticosteroids&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,700/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin within upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No history of angina&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith C. Bible, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Keith C. Bible, M.D., Ph.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

